Dr. Ali Al-Ghamrawy, Chairman of the Egyptian Drug Authority, held a meeting with representatives of the Chamber of Pharmaceutical, Cosmetics and Medical Supplies Industries, headed by Dr. Gamal El-Leithy, Chairman of the Chamber, and attended by Dr. Tamer Elhossieny, Vice Chairman of the Egyptian Drug Authority, to discuss several issues and topics of mutual interest and consider proposals aimed at developing the regulatory environment and supporting the sustainability and competitiveness of Egypt’s pharmaceutical industry.
Dr. Ali Al-Ghamrawy emphasized the Egyptian Drug Authority’s commitment to maintaining effective communication with industry partners and listening to their proposals and feedback. He noted that this approach contributes to achieving a balance between regulatory and oversight requirements on one hand and supporting the sustainability and competitiveness of the national pharmaceutical industry on the other, while contributing to the availability of pharmaceutical products and meeting the needs of the Egyptian market.
Representatives of the Pharmaceutical Industry Chamber, in turn, commended the Egyptian Drug Authority’s commitment to strengthening communication and dialogue with industry partners and listening to the challenges and proposals raised. They emphasized the importance of continuing this participatory approach to contribute to the development of the regulatory framework, facilitate procedures, and support the sustainability and competitiveness of the Egyptian pharmaceutical industry.
The meeting addressed several observations and proposals submitted by the Pharmaceutical Industry Chamber regarding certain regulatory decisions and their implementation mechanisms. The EDA listened to the views and observations of industry representatives and the challenges associated with implementation, while exchanging perspectives on appropriate approaches to addressing these matters in accordance with the applicable regulatory frameworks and rules.
Both sides also emphasized the importance of continuing coordination and consultation between the Egyptian Drug Authority and the Pharmaceutical Industry Chamber and working to assess the proposals raised in accordance with the applicable regulatory frameworks, in a manner that contributes to addressing challenges and supporting the stability of the pharmaceutical market.
This comes as part of the Egyptian Drug Authority’s commitment to strengthening partnership and continuous communication with all stakeholders across the pharmaceutical sector, supporting the development of the national industry, enhancing the stability and competitiveness of the pharmaceutical market, and ensuring the availability of safe, effective, and high-quality pharmaceutical products for Egyptian citizens.